DoW Kidney Cancer, Idea Development Award
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The fiscal year 2026 Kidney Cancer Research Program Idea Development Award is a federal grant opportunity administered by the Defense Health Agency Contracting Activity through the Congressionally Directed Medical Research Programs, aimed at advancing kidney cancer research to improve patient outcomes for Service Members, Veterans, and their families. Applications must present a scientifically rigorous, testable hypothesis with strong rationale and a well-defined research approach, with all proposed team members demonstrating expertise in kidney cancer. The program supports a unique Partnering Principal Investigator option, allowing two investigators to collaborate on a single project, where only the Initiating PI submits a pre-application, but both must submit full applications with distinct components, including a Partnership Statement and separate Statements of Work and budgets; failure of either application to proceed results in withdrawal of the entire proposal. The award carries a maximum funding cap of $900,000 for single-PI proposals and $1,200,000 for partnered applications over a three-year period, with no option for renewal or extension. Applicants must comply with strict submission protocols, including pre-applications via eBRAP by September 14, 2026, and full applications via eBRAP for intramural entities or Grants.gov for extramural organizations by September 28, 2026, with all documents submitted as individually named PDF files under specified page limits. A comprehensive set of attachments is required, including a 12-page Project Narrative, 3-page Statement of Work, 1-page Impact Statement, 3-page Animal Research Plan if applicable, and a 2-page Post-Award Progression Plan outlining translational pathways. Proposals must adhere to federal regulations, including human and animal research protections, PHS inclusion reporting, and open science standards such as ARRIVE and CONSORT. Key personnel must disclose all foreign affiliations under NSPM-33, and any failure to do so, or involvement with CDMRP review contractors, will result in administrative withdrawal. A SAM.gov registration with an active Unique Entity Identifier is mandatory, and applicants are subject to integrity reviews. Evaluations are conducted in two stages: first by peer reviewers assessing scientific merit including rationale, feasibility, personnel expertise, and data sharing plans; followed by programmatic review focusing on strategic alignment and potential impact on the field. Awards are made through a holistic trade-off process, not based on lowest cost, with emphasis on scientific quality and programmatic value. Classified research is prohibited, direct contact with peer reviewers is strictly forbidden,
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Timeline
Response Deadline
Organization & Contact Information
Full Description
Summary: The fiscal year 2026 (FY26) Kidney Cancer Research Program (KCRP) Idea Development Award (IDA) supports the development of high-impact ideas that advance the understanding of kidney cancer and ultimately lead to improved patient outcomes. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach. Personnel on the proposed team should have a strong background in kidney cancer research.
Distinctive Features:
· Partnering Principal Investigator Option: Supports meaningful and productive partnerships between two investigators, termed the Initiating Principal Investigator (PI) and Partnering PI, collaborating on a single application. Only the Initiating PI will submit a pre-application, but all PIs will need to submit full applications. The Partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.
